THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
FOR IMMEDIATE RELEASE
Microsaic Systems plc
("Microsaic" or the "Company")
Publication of
Annual Report & Accounts
Microsaic Systems plc (AIM: MSYS), the developer of micro-electronic instruments and provider of integrated analytical water testing solutions, provides an update on the expected publication date of its annual report and accounts for the year to 31 December 2023 (the "FY23 Accounts").
The FY23 Accounts will not be ready to be published by the close of business on 28 June 2024, being the effective deadline for publication under the AIM Rules for Companies. Consequently, the Company's shares are expected to be suspended from trading on AIM with effect from 07.30 a.m. on 1 July 2024, pending publication of the FY23 Accounts.
The Company is working diligently to support the completion of its audit and expects to publish its FY23 Accounts by the end of July 2024. A further announcement will be made in due course.
Microsaic Systems plc Bob Moore, Acting Executive Chairman |
+44 (0) 20 3657 0050 via TPI |
|
|
Singer Capital Markets (Nominated Adviser) Aubrey Powell / Oliver Platts |
+44 (0)20 7496 3000 |
|
|
Turner Pope Investments (TPI) Limited (Broker) Andy Thacker / James Pope |
+44 (0) 20 3657 0050 |
About Microsaic Systems and Modern Water
Microsaic is highly experienced in microelectronics and development of instrumentation. Having acquired the Modern Water business it has reset, diversified and widened its capabilities into broader based analytical equipment supply and services company with combined technologies resulting in comprehensive water testing capabilities. The Company has an extensive existing and newly acquired innovative patent portfolio in industry-leading technology designed and developed for "Industry 4.0" application serving markets in diversified Industries, Human and Environmental Health. Microsaic's micro-mass spectrometer system and Modern Water water testing solutions enables analytical detection and characterisation at the point-of-need, whether within a mobile testing capability, conventional laboratory setting, or within a bioprocessing facility for continuous detection of data at multiple steps in the process workflow.
Microsaic's products and solutions are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing and point-of-need applications.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.